Core Insights - QuidelOrtho Corporation showcases its leadership in transfusion medicine with the FDA approval of the MTS DAT Card and the expansion of its immunohematology portfolio at the AABB 2025 Annual Meeting [1][2][3] Product Highlights - The MTS DAT Card completes the gel-based solution for direct antiglobulin testing, enhancing laboratory efficiency and reliability when paired with the ORTHO VISION Platform [2][3] - The ORTHO VISION Max Swift Analyzer is designed for high-throughput labs, offering speed, reliability, and automation with increased sample and reagent capacity [7] - The ORTHO CONNECT Lab Management Software streamlines operations and addresses staffing challenges in laboratory networks [7] Educational Contributions - QuidelOrtho's participation in the AABB Annual Meeting includes sessions on Rh(D) antigen identification, gel test typing for DARA patients, and advanced immunohematology techniques for complex serological cases [3][7]